LONDON (dpa-AFX) - Genmab A/S (GNMSF.PK) and GlaxoSmithKline (GSK, GSK.L) announced the submission of a New Drug Application to the Japanese Ministry of Health, Labor and Welfare for Arzerra (ofatumumab) for the treatment of chronic lymphocytic leukemia.
'This marks another important achievement in our collaboration with GSK for Arzerra,' said Jan van de Winkel, Chief Executive Officer of Genmab. 'The global commercialization of Arzerra continues as planned.'
Today's announcement does not affect Genmab's financial guidance for 2012.
Copyright RTT News/dpa-AFX